| Trial Identifier: | D5165C00001 |
| Sponsor: | AstraZeneca |
| NCTID:: | NCT02454933 |
| Start Date: | July 2015 |
| Primary Completion Date: | August 2017 |
| Study Completion Date: | December 2022 |
| Condition: | Lung Cancer |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| English translation | |
| Korean Translation | |
| Chinese Translation | |
| French Translation |
| Country | Location |
|---|---|
| CA, ON | Toronto, ON, CA, M5G 2M9 |
| KR | Busan, KR, 47392 |
| KR | Daegu, KR, 42601 |
| KR | Incheon, KR, 21565 |
| KR | Jinju-si, KR, 660-702 |
| KR | Seongnam-si, KR, 13620 |
| KR | Seoul, KR, 156-707 |
| KR | Seoul, KR, 03181 |
| KR | Seoul, KR, 03080 |
| KR | Ulsan, KR, 44033 |
| TW | Kaohsiung, TW, 82445 |
| TW | Taichung, TW, 40705 |
| TW | Taipei, TW, 10002 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company